During the past decade, AOU Università degli Studi della Campania "Luigi Vanvitelli" conducted 54 clinical trials. In the 10-year time frame, 54 clinical trials started and 10 clinical trials were completed, i.e. on average, 18.5% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 10 clinical trials were completed. i.e. 30.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "AOU Università degli Studi della Campania "Luigi Vanvitelli"" #1 sponsor was "Agios Pharmaceuticals, Inc." with 5 trials, followed by "Janssen Research & Development, LLC" with 5 trials sponsored, "National Cancer Institute, Naples" with 5 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored and "Celgene" with 3 trials sponsored. Other sponsors include 32 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "AOU Università degli Studi della Campania "Luigi Vanvitelli"" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "Mario Negri Institute for Pharmacological Research" with 2 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 2 trials as a collaborator, "ARMO BioSciences" with 1 trials as a collaborator and "Bruschettini S.r.l." with 1 trials as a collaborator. Other collaborators include 15 different institutions and companies that were collaborators in the rest 25 trials.

According to Clinical.Site data, the most researched conditions in "AOU Università degli Studi della Campania "Luigi Vanvitelli"" are "Pyruvate Kinase Deficiency" (3 trials), "Schizophrenia" (3 trials), "Anemia, Hemolytic" (2 trials), "Arthritis, Psoriatic" (2 trials) and "Chronic Kidney Disease" (2 trials). Many other conditions were trialed in "AOU Università degli Studi della Campania "Luigi Vanvitelli"" in a lesser frequency.

Most popular intervention types in "AOU Università degli Studi della Campania "Luigi Vanvitelli"" are "Drug" (55 trials), "Other" (5 trials), "Biological" (2 trials), "Device" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Cetuximab" (4 trials), "Bevacizumab" (3 trials), "Carboplatin" (3 trials) and "Guselkumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "AOU Università degli Studi della Campania "Luigi Vanvitelli"" are 54 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "AOU Università degli Studi della Campania "Luigi Vanvitelli"". undefined are not yet recruiting, 24 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in AOU Università degli Studi della Campania "Luigi Vanvitelli", undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in AOU Università degli Studi della Campania "Luigi Vanvitelli", 0 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 32 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 0 trials that are defined as “Not Applicable".

AOU Università degli Studi della Campania "Luigi Vanvitelli" has several departments that took part in Clinical trials: "AOU Seconda Università degli Studi; Dip.Assistenziale Integrato Medicina Int-I Clinica Neurologica" - 4 trials